EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions

Mays M Jarrah, Humaid O Al-Shamsi, Ziad Abuhelwa, Yasser Bustanji, Mohammad H Semreen iD, Ross A McKinnon, Michael J Sorich, Ashley M Hopkins, Ahmad Y Abuhelwa iD

European Journal of Haematology · 2026-07 · 117 (1) · 100-116

DOI: 10.1111/ejh.70177 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 30.03.2026. Verfasst von Mays M Jarrah und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, University of Sharjah, Sharjah, UAE. Hauptthemen laut MEDLINE: Multiple Myeloma, Predictive Learning Models. Die Arbeit nennt 43 Literaturangaben. Gefördert von: University of Sharjah, National Health and Medical Research Council (NHMRC), Tour De Cure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Multiple myeloma (MM) is characterized by substantial clinical heterogeneity, leading to wide variability in treatment response and toxicity. Although numerous prognostic tools exist, relatively few models estimate outcomes conditional on a specific therapeutic regimen. Treatment‐specific prediction models are an important step toward individualized therapy selection. This review synthesizes the current landscape of treatment‐specific clinical prediction models in MM.

Methods

A structured search of PubMed and Embase/Scopus identified multivariable clinical prediction models developed within a static treatment framework, evaluating treatment‐specific therapeutic or toxicity‐related outcomes in MM. Information was extracted on treatment regimens, predictors, modeling methods, validation strategies, and reporting of clinical utility.

Results

Thirteen models were identified, evaluating therapeutic ( n = 10) or toxicity‐related ( n = 3) outcomes across regimens including bortezomib‐based induction, daratumumab‐containing combinations, ixazomib‐based triplets, and CAR‐T therapy. Predictors were mainly routine clinical and laboratory variables, with limited integration of cytogenetics or patient‐reported outcomes. Most models used traditional regression methods; calibration was inconsistently reported, and external validation was performed in seven studies. Decision curve analysis was included in only two models.

Conclusions

Methodological and translational gaps remain, including limited transparency, scarce external validation, and lack of patient‐reported or longitudinal predictors. None of the models have been implemented as online calculators or integrated into electronic decision‐support systems, limiting real‐world uptake. Addressing these gaps is essential for developing clinically meaningful prediction tools to support personalized treatment in MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPredictive Learning ModelsHumansAntineoplastic Combined Chemotherapy ProtocolsDisease ManagementPrecision MedicinePrognosisTreatment Outcome

Stichwörter der Autor:innen

machine learningmultiple myelomapersonalized medicineprediction modelsprognostic modellingrisk stratificationtoxicity predictiontreatment‐specific outcomes

Autor:innen und Institutionen

  • College of Pharmacy, University of Sharjah, Sharjah, UAE.
  • Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, UAE.
  • Department of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UAE.
  • College of Medicine, Ras Al Khaimah Medical and Health Sciences, Ras Al Khaimah, UAE.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Hematology and Medical Oncology, University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

ORCID-Profile: Mohammad H Semreen, Ahmad Y Abuhelwa

Förderung

  • University of Sharjah
  • National Health and Medical Research Council (NHMRC)
  • Tour De Cure

Zitieren

APA

Jarrah, M. M., Al-Shamsi, H. O., Abuhelwa, Z., Bustanji, Y., Semreen, M. H., McKinnon, R. A., Sorich, M. J., Hopkins, A. M., & Abuhelwa, A. Y. (2026). Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions. European Journal of Haematology, 117(1), 100-116. https://doi.org/10.1111/ejh.70177

Vancouver

Jarrah MM, Al-Shamsi HO, Abuhelwa Z, Bustanji Y, Semreen MH, McKinnon RA, et al. Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions. European Journal of Haematology. 2026;117(1):100-116. doi:10.1111/ejh.70177

BibTeX
@article{Jarrah2026,
  author = {Jarrah, Mays M and Al-Shamsi, Humaid O and Abuhelwa, Ziad and Bustanji, Yasser and Semreen, Mohammad H and McKinnon, Ross A and Sorich, Michael J and Hopkins, Ashley M and Abuhelwa, Ahmad Y},
  title = {Treatment‐Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {1},
  pages = {100--116},
  doi = {10.1111/ejh.70177}
}
Kostenlos starten →